Skip to main content
Journal cover image

Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.

Publication ,  Journal Article
Myhre, PL; Vaduganathan, M; Claggett, BL; Miao, ZM; Jhund, PS; de Boer, RA; Hernandez, AF; Inzucchi, SE; Kosiborod, MN; Lam, CSP; Martinez, F ...
Published in: JACC Heart Fail
December 2022

BACKGROUND: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is used for diagnostic and prognostic evaluation in heart failure (HF). Previous clinical trials in heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) have shown potential heterogeneity in the treatment response by baseline NT-proBNP levels. OBJECTIVES: The purpose of this study was to assess the treatment effect of dapagliflozin across baseline levels of NT-proBNP among patients with HFmrEF or HFpEF. METHODS: This was a post hoc analysis from DELIVER (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure), a randomized, placebo-controlled trial of dapagliflozin in patients with HFmrEF or HFpEF. Elevated NT-proBNP was part of the inclusion criteria (≥300 ng/L for non-atrial fibrillation or flutter [AFF]; ≥600 ng/L for AFF). Baseline NT-proBNP was categorized in quartiles and additionally analyzed continuously. The primary composite outcome was cardiovascular death or worsening HF events. RESULTS: Among the 6,262 included patients (mean: 71.7 years and 3,516 [56%] men), the median baseline concentration of NT-proBNP was 716 (Q1-Q3: 469-1,280) ng/L and 1,399 (Q1-Q3: 962-2,212) ng/L for non-AFF and AFF, respectively. Higher NT-proBNP levels were linearly associated with a greater risk of the primary outcome (adjusted HR for log2NTpro-BNP was 1.53 [95% CI: 1.46-1.62] and Q4 vs Q1: 3.46 [95% CI: 2.48-4.22]; P < 0.001), with consistent results regardless of AFF status. The clinical benefit of dapagliflozin was present irrespective of baseline NT-proBNP concentration (P value for interaction = 0.40 by quartiles and = 0.19 continuously for the primary outcome) and the absolute risk reduction was, therefore, greater with higher NT-proBNP concentrations. The effect on health status and safety of dapagliflozin was similarly consistent across NT-proBNP quartiles. CONCLUSIONS: Dapagliflozin is safe and improves outcomes irrespective of baseline NT-proBNP concentrations in HFmrEF or HFpEF, with the greatest absolute benefit likely seen in patients with higher NT-proBNP concentrations. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JACC Heart Fail

DOI

EISSN

2213-1787

Publication Date

December 2022

Volume

10

Issue

12

Start / End Page

902 / 913

Location

United States

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Stroke Volume
  • Prognosis
  • Peptide Fragments
  • Natriuretic Peptide, Brain
  • Male
  • Humans
  • Heart Failure
  • Female
  • Biomarkers
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Myhre, P. L., Vaduganathan, M., Claggett, B. L., Miao, Z. M., Jhund, P. S., de Boer, R. A., … Solomon, S. D. (2022). Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail, 10(12), 902–913. https://doi.org/10.1016/j.jchf.2022.08.007
Myhre, Peder L., Muthiah Vaduganathan, Brian L. Claggett, Zi Michael Miao, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, et al. “Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.JACC Heart Fail 10, no. 12 (December 2022): 902–13. https://doi.org/10.1016/j.jchf.2022.08.007.
Myhre PL, Vaduganathan M, Claggett BL, Miao ZM, Jhund PS, de Boer RA, et al. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. 2022 Dec;10(12):902–13.
Myhre, Peder L., et al. “Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.JACC Heart Fail, vol. 10, no. 12, Dec. 2022, pp. 902–13. Pubmed, doi:10.1016/j.jchf.2022.08.007.
Myhre PL, Vaduganathan M, Claggett BL, Miao ZM, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. 2022 Dec;10(12):902–913.
Journal cover image

Published In

JACC Heart Fail

DOI

EISSN

2213-1787

Publication Date

December 2022

Volume

10

Issue

12

Start / End Page

902 / 913

Location

United States

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Stroke Volume
  • Prognosis
  • Peptide Fragments
  • Natriuretic Peptide, Brain
  • Male
  • Humans
  • Heart Failure
  • Female
  • Biomarkers